GlassScriptPhysician profile
John W Van Wert
NPI 1437151313
$1,853.64
in general payments reported to CMS, 2019-2025
28 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $56.91 · 2021: $192 · 2022: $415 · 2023: $355 · 2024: $142 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.46 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $181.11 | 2019-2025 | |
| Astellas Pharma US INC | $167.95 | 2023-2024 | Veozah |
| Solta Medical, A Division of Bausch Health US, LLC | $137.44 | 2020-2025 | Clear & Brilliant, Fraxel |
| Smith+Nephew, INC. | $119.68 | 2019-2025 | Stravix Pl |
| Pacira Pharmaceuticals Incorporated | $100.00 | 2019 | |
| Hologic Sales and Service, LLC | $96.95 | 2019-2023 | Acessa Provu System, Thinprep 2000 Processor, Aptima |
| Currax Pharmaceuticals LLC | $95.22 | 2021-2024 | Contrave, Onzetra Xsail |
| Coopersurgical, INC. | $95.16 | 2022-2025 | Sos, Mara Console, Paragard T 380a |
| Novo Nordisk INC | $81.70 | 2019 | |
| Agile Therapeutics, INC. | $79.97 | 2021-2023 | Twirla |
| Mylan Pharmaceuticals INC. | $75.01 | 2019-2022 | |
| Millicent US INC | $73.89 | 2022-2023 | Femring, Intrarosa |
| Daiichi Sankyo INC. | $66.54 | 2019-2022 | |
| Allergan, INC. | $62.71 | 2019-2020 | |
| Evofem Biosciences, INC. | $57.48 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mycovia Pharmaceuticals, INC. | $46.76 | 2023 | Vivjoa |
| Therapeuticsmd, INC. | $45.18 | 2020-2021 | |
| Organon LLC | $42.19 | 2022-2023 | Nexplanon |
| Exeltis, USA INC. | $38.34 | 2022-2023 | Slynd |
| Pfizer INC. | $36.59 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $33.42 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.26 | 2019-2022 | |
| Nalpropion Pharmaceuticals LLC | $19.85 | 2019 | |
| Gynesonics, INC. | $16.42 | 2022 | |
| Ascend Therapeutics US, LLC | $16.00 | 2021 | |
| Guard Medical INC. | $14.70 | 2023 | Npseal Large, Npseal (5), Npseal Medium |
| Ferring Pharmaceuticals INC. | $12.81 | 2019 | |
| Minerva Surgical, INC | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Van Wert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.